| Ytd | -29.24% | |
| 1y | -31.83% |
| Open | 7.37 | Prev Close | 7.37 | Low | 7.21 | High | 7.45 | Mkt Cap | 1.13B |
| Vol | 1.37M | Avg Vol | 600.13K | EPS | -1.87 | P/E | N/A | Forward P/E | -3.59 |
| Beta | 1.36 | Short Ratio | 6.71 | Inst. Own | 66.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-17 | 50-d Avg | 8.92 | 200-d Avg | 9.80 | 1yr Est | 17.63 |
IMTX News
Kyntra Bio (NASDAQ: KYNB - Get Free Report) and Immatics (NASDAQ: IMTX - Get Free Report) are both s
Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s stock price reached a new 52-week low during mid-da
Immatics N.V. (NASDAQ: IMTX - Get Free Report) shares saw unusually-strong trading volume on Wednesd
Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination a
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), the global leader in pre
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.53) per share which missed the analyst conse
Houston, Texas and Tuebingen, Germany, August 18, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or
Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned a consensus recommendati
Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or t
Immatics is evolving into a PRAME-focused oncology platform with three monetization paths, not just
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, de
IMA401 achieved deep and durable responses in various indications, including melanoma and head and n
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expans
Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate
Immatics (NASDAQ:IMTX) reported quarterly losses of $(0.50) per share which missed the analyst conse
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggere
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co
Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or
Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in prec
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday
On Wednesday, 807 companies reached new 52-week lows.
On Wednesday, 90 companies set new 52-week lows.
During Tuesday's session, 454 stocks hit new 52-week lows.
On Monday, 671 companies achieved new lows for the year.
On Friday, 368 stocks hit new 52-week lows.
On Wednesday, 348 companies hit new 52-week lows.
During Tuesday's trading, 505 companies set new 52-week lows.
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insid
On Tuesday, 88 companies set new 52-week lows.
Wednesday morning saw 162 companies set new 52-week highs.
An ETF based on special purpose acquisition companies that trades on a U.S. exchange is now availabl